Correlative evidence suggests that the EIF2S3-mediated ER stress-UPR axis represents a potential candidate therapeutic target to overcome NCIT resistance, generating testable hypotheses to advance precision oncology for resectable locally advanced ESCC. This evidence concerns the gene EIF2S3 and esophageal squamous cell carcinoma.